Aptose Biosciences logo

Aptose BiosciencesNASDAQ: APTO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

16 March 1992

Next earnings report:

26 March 2025

Last dividends:

N/A

Next dividends:

N/A
$5.61 M
-85%vs. 3y high
13%vs. sector
-vs. 3y high
-vs. sector
-100%vs. 3y high
12%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 21 Nov 2024 00:09:29 GMT
$0.29$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

APTO Latest News

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
globenewswire.com20 November 2024 Sentiment: POSITIVE

TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sites Favorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and azacitidine to potentially address larger AML populations Study execution update is expected during ASH 2024 SAN DIEGO and TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced initiation of the TUSCANY study, tuspetinib (TUS) in combination therapy with azacitidine (AZA) and venetoclax (VEN) as a frontline triplet combination therapy for patients newly diagnosed with acute myeloid leukemia, or AML. The trial is being conducted at multiple U.S. clinical sites.

Aptose Reports Results for the Third Quarter 2024
globenewswire.com08 November 2024 Sentiment: POSITIVE

Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
globenewswire.com30 August 2024 Sentiment: POSITIVE

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Aptose Announces Adjournment of its Special Meeting of Shareholders
globenewswire.com15 August 2024 Sentiment: NEUTRAL

SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that its special meeting of shareholders (the "Meeting") convened on August 15, 2024, at 1:00 p.m. (ET) has been adjourned to September 5, 2024 at 1 p.m.

Aptose Announces Results from Annual and Special Meeting of Shareholders
globenewswire.com18 June 2024 Sentiment: POSITIVE

SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company's annual and special meeting of shareholders held today, June 18, 2024 (the “Meeting”). A total of 8,101,527 common shares of the Company, representing 49.67% of the common shares of the Company entitled to be voted, were represented by shareholders present or represented by proxy at the Meeting.

Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
globenewswire.com14 June 2024 Sentiment: POSITIVE

TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in Difficult-to-treat Genetic Subgroups, FLT3 Wildtype AML TUS Shown to Target VEN Resistance Mechanisms and Retain Activity on VEN-Resistant AML Cells in Preclinical Study TUS+VEN+Azacitidine (AZA) Triplet Trial to Treat Newly Diagnosed AML Patients; Clinical Sites Being Activated SAN DIEGO and TORONTO, June 14, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced a clinical poster presentation and a preclinical e-poster at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain. Tuspetinib (TUS) is being developed as a TUS + venetoclax (VEN) + hypomethylating agent (HMA) triple drug combination (or TUS+VEN+HMA triplet) as frontline therapy for newly diagnosed AML patients.

Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com13 June 2024 Sentiment: POSITIVE

Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aptose Biosciences Inc. (APTO) Q1 2024 Earnings Call Transcript
Seeking Alpha14 May 2024 Sentiment: POSITIVE

Aptose Biosciences Inc. will be holding its Q1 2024 Earnings Conference Call on May 14, 2024 at 5:00 PM ET. Key company representatives participating in the call include Susan Pietropaolo, William Rice, Rafael Bejar, and Fletcher Payne. The conference call will be moderated by Joe Pantginis from H.C. Wainwright. Good afternoon, and welcome to the call.

What Makes Aptose Biosciences (APTO) a New Buy Stock
Zacks Investment Research05 April 2024 Sentiment: POSITIVE

Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript
Seeking Alpha26 March 2024 Sentiment: POSITIVE

Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript

  • 1(current)

What type of business is Aptose Biosciences?

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

What sector is Aptose Biosciences in?

Aptose Biosciences is in the Healthcare sector

What industry is Aptose Biosciences in?

Aptose Biosciences is in the Biotechnology industry

What country is Aptose Biosciences from?

Aptose Biosciences is headquartered in Canada

When did Aptose Biosciences go public?

Aptose Biosciences initial public offering (IPO) was on 16 March 1992

What is Aptose Biosciences website?

https://www.aptose.com

Is Aptose Biosciences in the S&P 500?

No, Aptose Biosciences is not included in the S&P 500 index

Is Aptose Biosciences in the NASDAQ 100?

No, Aptose Biosciences is not included in the NASDAQ 100 index

Is Aptose Biosciences in the Dow Jones?

No, Aptose Biosciences is not included in the Dow Jones index

When was Aptose Biosciences the previous earnings report?

No data

When does Aptose Biosciences earnings report?

The next expected earnings date for Aptose Biosciences is 26 March 2025